Incretin-based therapy: renal effects

Incretin-based therapy: renal effects

Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic ki...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anton Ivanovich Korbut, Vadim Valerievich Klimontov
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2016-01-01
Series:	Сахарный диабет
Subjects:	diabetes diabetic nephropathy glucagon-like peptide-1 dipeptidyl peptidase-4 incretin-based therapy
Online Access:	https://www.dia-endojournals.ru/jour/article/view/7727
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)

Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications
by: Yaswanth Kuthati, et al.
Published: (2025-04-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-11-01)

Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
by: Qin Li, et al.
Published: (2025-07-01)

Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study
by: Makoto Ohara, et al.
Published: (2025-04-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control studyResearch in context
by: Julien Bezin, et al.
Published: (2025-02-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
by: D. V. Kurkin, et al.
Published: (2023-05-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Incretin‐Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists—A Review
by: Ousman Mohammed, et al.
Published: (2025-07-01)

Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
by: Oscar Hou‐In Chou, et al.
Published: (2025-06-01)

Role of DPP-4 and NPY Family Peptides in Gastrointestinal Symptoms Associated with Obesity and Type 2 Diabetes Mellitus
by: Mantas Malinauskas, et al.
Published: (2025-03-01)

Inсretin-based therapy in patients with type 2 diabetes and chronic kidney disease
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-09-01)

Protein hydrolysate as a source of bioactive peptides in diabetic food products
by: O. V. Zinina, et al.
Published: (2024-01-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
by: M Elle Saine, et al.
Published: (2015-04-01)

PANCREATIC AND EXTRA-PANCREATIC EFFECTS OF INCRETINS AND PERSPECTIVES FOR STUDYING ENTEROINSULIN HORMONAL SYSTEM DURING GESTATIONAL DISORDER OF CARBOHYDRATE METABOLISM
by: T. V. Saprina, et al.
Published: (2013-06-01)

Research progress on the association of bullous pemphigoid with type 2 diabetes mellitus
by: ZHANG Ruohan, et al.
Published: (2025-03-01)

Deciphering new biomolecules, antioxidants, and human dipeptidyl Peptidase-4 inhibitor potential of green celery: Bioprospecting insights from molecular docking and in vitro investigation
by: Fan Maitri Aldian, et al.
Published: (2025-10-01)

Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
by: Vincenzo Trapanese, et al.
Published: (2025-05-01)

Hypoglycemic Therapy and the Course of Post-Covid Syndrome, is There a Connection?
by: G. A. Ignatenko, et al.
Published: (2023-04-01)

Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity
by: M. A. Druzhilov, et al.
Published: (2022-05-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Targeting dipeptidyl peptidase-8/9 to combat inflammation-induced osteoclastogenesis in RAW264.7 macrophages and analysis of anti-osteoclastogenesis potential of chrysin
by: Syed Sufian Ahmad, et al.
Published: (2025-04-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study
by: Yu-Ching Li, et al.
Published: (2025-04-01)

The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature
by: Jakub Waszczyński, et al.
Published: (2025-01-01)

The Gut Microbiome’s Influence on Incretins and Impact on Blood Glucose Control
by: Ajay S. Dulai, et al.
Published: (2024-11-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
by: Xiaoke Dou, et al.
Published: (2025-03-01)